Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has announced its participation in two upcoming investor healthcare conferences. The company's management will be featured in fireside chats at:

• The Wells Fargo Healthcare Conference on Sept. 4, 2024, at 1:30pm ET, with CFO Scott Leffler
• The Morgan Stanley Healthcare Conference on Sept. 5, 2024, at 7:00am ET, with President and CEO Paul J. Diaz

Investors and interested parties can access live and archived webcasts of both presentations through the company's investor relations website at investor.myriad.com.

News Market Reaction – MYGN

+1.05%

+1.05% Session move

In the trading session that priced this news, MYGN gained 1.05%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences.

• The Wells Fargo Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, on Sept. 4, 2024 at 1:30pm ET.
• The Morgan Stanley Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Sept. 5, 2024 at 7:00am ET.

Links to the live and archived webcasts of both presentations can be viewed at investor.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com

Media Contact 
Glenn Farrell 
(385) 318-3718 
PR@myriad.com 

FAQ

When is Myriad Genetics (MYGN) participating in the Wells Fargo Healthcare Conference?

Myriad Genetics (MYGN) is participating in the Wells Fargo Healthcare Conference on September 4, 2024, at 1:30pm ET.

Who will represent Myriad Genetics (MYGN) at the Morgan Stanley Healthcare Conference?

Paul J. Diaz, President and CEO of Myriad Genetics (MYGN), will represent the company at the Morgan Stanley Healthcare Conference on September 5, 2024, at 7:00am ET.

How can investors access the webcasts of Myriad Genetics (MYGN) conference presentations?

Investors can access live and archived webcasts of Myriad Genetics (MYGN) conference presentations through the company's investor relations website at investor.myriad.com.

What type of company is Myriad Genetics (MYGN)?

Myriad Genetics (MYGN) is a leader in genetic testing and precision medicine, listed on NASDAQ.